Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
Abstract Background Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome drug resistance. Methods We...
Main Authors: | Hee Sun Park, Da‐Hye Lee, Da Hyun Kang, Min‐Kyung Yeo, Goeun Bae, Dahye Lee, Geon Yoo, Ju‐Ock Kim, Eunyoung Moon, Yang Hoon Huh, Sang‐Hee Lee, Eun‐Kyeong Jo, Sang Yeon Cho, Jeong Eun Lee, Chaeuk Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-02-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3734 |
Similar Items
-
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01) -
New Insights into the Clinical Implications of Yes-Associated Protein in Lung Cancer: Roles in Drug Resistance, Tumor Immunity, Autophagy, and Organoid Development
by: Geon Yoo, et al.
Published: (2021-06-01) -
Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01) -
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
by: Jeng-Shiuan Tsai, et al.
Published: (2021-09-01) -
Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)